Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet, Intellia has a very long way to go before it has a chance to commercialize any of its product candidates, and there's nothing to suggest it's on the verge of suddenly hitting the lottery and bringing in hundreds of millions in revenue.
So what are the analysts getting at with their estimates, and should you buy this stock?
Intellia's pipeline has two focuses, both of which pertain to its use of gene-editing technologies to treat or cure illnesses.
Source Fool.com
Intellia Therapeutics Inc Aktie
20,57 €
1,96 %
Die Intellia Therapeutics Inc Aktie verzeichnet mehrere Buy-Einschätzungen, was auf eine positive Tendenz hindeutet.
Mit einem Kursziel von 60 € für Intellia Therapeutics Inc, würde dies eine mehr als zweifache Steigerung des aktuellen Kurses von 20.57 € bedeuten.
